dexamethasone sparing

Phase 2

MMahidol University

dexamethasone sparing is one of 2 therapeutic programs targeting Cancer (Solid Tumors). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cancer (solid Tumors)Recruiting

Cancer (solid Tumors)Phase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Cancer (solid Tumors)

#DrugCompanyPhaseTrials

Ezabenlimab

Boehringer Ingelheim

Phase 1

2 2

dexamethasone sparing

MMahidol University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Cancer (solid Tumors)

NCT07699276

Clinical

Trials by Indication[1]

Cancer (Solid Tumors)1 trial

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study

Recruiting·MMahidol University·Phase 2·NCT07699276·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dexamethasone sparing. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for dexamethasone sparing. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mahidol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMahidol University

dexamethasone sparing

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cancer (Solid Tumors)1 trial

References

Drug Info

Quick Facts

Related News